SkinBioTherapeutics Plc
SBTX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | £5 | £1 | £0 | £0 |
| % Growth | 283.6% | 815.5% | 76.6% | – |
| Cost of Goods Sold | £2 | £1 | £0 | £0 |
| Gross Profit | £3 | £1 | £0 | £0 |
| % Margin | 58.3% | 56.5% | 64.5% | 60.6% |
| R&D Expenses | £0 | £1 | £1 | £1 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £3 | £3 | £2 | £2 |
| Operating Expenses | £4 | £4 | £3 | £3 |
| Operating Income | -£1 | -£3 | -£3 | -£3 |
| % Margin | -17.8% | -240.3% | -2,271.3% | -3,988.8% |
| Other Income/Exp. Net | £0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£1 | -£3 | -£3 | -£3 |
| Tax Expense | -£0 | -£0 | -£0 | -£0 |
| Net Income | -£1 | -£3 | -£3 | -£3 |
| % Margin | -15% | -237.9% | -2,146.9% | -3,735.4% |
| EPS | -0.003 | -0.015 | -0.017 | -0.018 |
| % Growth | 79.9% | 10.5% | 3.4% | – |
| EPS Diluted | -0.003 | -0.015 | -0.017 | -0.018 |
| Weighted Avg Shares Out | 228 | 186 | 165 | 157 |
| Weighted Avg Shares Out Dil | 228 | 186 | 165 | 157 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£3 | -£3 | -£3 |
| % Margin | -4.2% | -225.1% | -2,237.8% | -3,949.1% |